AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:

* * *

Extended-Interval Tarlatamab Dosing Shows Consistent Activity and Safety in Previously Treated Small Cell Lung Cancer

*

(SEOUL, Republic of Korea -Saturday, September 12th, 6:15 p.m. Korea Standard Time) - Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety, and pharmacok . . .

Click here for more information about our products